Transitioning Patients Back to Community Practices Following CAR T

Opinion
Video

Members of the panel discuss their criteria for determining when a patient is ready to transition back to community oncologists after they receive CAR T-cell therapy.

  • Dr. Krishnan: What criteria or thresholds do you use to determine when a patient is ready for transition back to the community oncologist after CAR-T therapy? (e.g. time since infusion, resolution of toxicities, evidence of response)

  • Dr. Park: At what point in the patient's recovery course after CAR-T do you think it is ideal for their care to transition back to the community oncologist? What factors influence this timing?
    1. How much clinical/treatment detail from the CAR-T process at the academic center is typically provided or needed by community providers for optimal long-term monitoring and follow-up of the patient?
Recent Videos
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD
4 KOLs are featured in this panel.
4 KOLs are featured in this panel.
2 KOLs are featured in this series
2 KOLs are featured in this series
A panel of 4 experts on multiple myeloma
Related Content